Huntington's disease (HD) is an inherited neurological illness causing involuntary movements, severe emotional disturbance and cognitive decline. In the United States alone, about 30,000 people have HD. In addition, 35,000 people exhibit some symptoms and 75,000 people carry the abnormal gene that will cause them to develop the disease. There is no cure for this fatal disease.
A single abnormal gene produces HD. In 1993, scientists finally isolated the HD gene on chromosome 4. The gene codes for production of a protein called "huntingtin," whose function is still unknown. But the defective version of the gene has excessive repeats of a three-base sequence, "CAG." In the normal huntingtin gene, this sequence is repeated between 11 and 29 times. In the mutant gene, the repeat occurs over and over again, from 40 times to more than 80.
This defect causes the resulting huntingtin protein to be malformed, prone to clumping in the brain and causing the death of nearby nerve cells. Cells of the basal ganglia, a brain area responsible for coordinating movement, and of the cortex, which controls thought, perception and memory, are most often affected.
Since the gene that causes HD is dominant, each child of an HD parent has a 50-50 chance of inheriting the HD gene. The child needs only one copy of the gene from either parent to develop the disease. A person who inherits the HD gene, and survives long enough, will sooner or later develop the disease. If the child does not inherit the defective gene, the child will not get the disease nor pass the gene on to subsequent generations. Symptoms of HD generally appear in mid-life.
The 1993 discovery of the gene, which triggers HD when it malfunctions, jump-started research on this devastating disease. Scientists hope that a multi-faceted approach will lead to a cure.
Research is proceeding in many directions:
These many avenues of research have recently converged in a promising discovery that suggests a treatment for HD: scientists at the University of California (UC) at Irvine, successfully prevented cell death in a Drosophila fruit fly model that carries the HD gene defect. UC Irvine researchers believe they've discovered how the genetic mutation alters chemical pathways to cause the disease. By identifying these changes, researchers believe they may have found an effective way to slow or prevent the disease.
The drug used by UC Irvine researchers to prevent the cell death in the fruit fly is known as an HDAC inhibitor, and is currently in clinical trials for treating cancer in humans. This could speed up human trials of the drug in Huntington's disease patients.
Top of page
The discovery of the HD gene led to a genetic test to make or confirm the diagnosis of Huntington's disease. Using a blood sample, the genetic test analyzes DNA for the HD mutation by counting the number of CAG repeats in the huntingtin gene. Individuals who do not have HD usually have 28 or fewer repeats. Individuals with HD usually have 40 or more repeats.
Deciding to be tested for Huntington's disease can be difficult. Individuals consider genetic testing to confirm a diagnosis when clear symptoms are present and there is a documented family history of HD. Others who have a parent with the disease elect to be tested to resolve uncertainty about their future. A negative test relieves anxiety and uncertainty. A positive test enables individuals to make decisions about careers, marriage and families.
Some who are at risk choose not to take the test. They choose to live with the uncertainty of being at risk and to forgo the emotional consequences of a positive result, as well as possible losses of insurance and employment. Genetic counselors can help individuals make the difficult decisions about testing.
Prospective parents consider prenatal testing when one parent has been diagnosed with Huntington's disease or has been found to carry the gene. Prenatal testing can show whether the child will inherit the defective gene. To test the fetus, DNA is extracted from fetal cells via CVS (chorionic villi sampling) or amniocentesis. If the fetus tests positive, parents can make decisions about whether to terminate the pregnancy.
Top of page
Currently, NHGRI is not conducting clinical studies on Huntington's Disease.
Top of page
Top of page
Last Updated: November 17, 2011